Study Shows Apitegromab Preserves Lean Mass During Weight Loss in U.S. Trial
A recent phase 2 trial conducted across seven sites in the United States has demonstrated that apitegromab significantly preserves lean mass during weight loss induced by tirzepatide. The trial, known as EMBRAZE, was a randomized, double-blind, placebo-controlled study involving adults with specific body mass index (BMI) criteria. Participants were administered apitegromab or a placebo alongside tirzepatide, an incretin mimetic therapy, over a 24-week period. The study found that those receiving apitegromab retained 54.9% more lean mass compared to the placebo group, with lean mass loss being significantly lower in the apitegromab group. The trial also reported that the total body weight loss was similar between both groups, but the composition of the weight loss differed, with the apitegromab group losing a larger proportion of fat mass. 
